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Aims: EA‐230 is a newly developed synthetic linear tetrapeptide (AQGV) derived
from the chorionic gonadotropin hormone (β‐hCG). We investigated the pharmacoki-
netics, safety and tolerability of EA‐230 in healthy subjects using different adminis-
tration strategies.
Methods: Double‐blind, randomized, placebo‐controlled, dose‐escalating phase I
studies in healthy subjects using intravenous administration were conducted. In the
single dosage study, 32 subjects were assigned to four single dosage groups (1, 3,
10 or 30 mg/kg). In the multiple dosage study, 24 subjects were assigned to three
dosage groups (10, 20 or 30 mg/kg, thrice daily for 3 days). In the continuous dosage
study, 24 subjects were assigned to three dosage groups (15, 30, or 90 mg/kg/hour
for 2 hours). Pharmacokinetics, safety and tolerability assessments were performed
up to 14 days.
Results: The highest dosage of EA‐230 (continuous infusion of 90 mg/kg/hour
for 2 hours) showed more than proportional increases in exposure (Cmax136%;
AUC0‐last137%), a large volume of distribution (geometric mean and 95% CI: 13
[3–58] L/kg), a high clearance rate (26 [15–43] L/h/kg), and a short half‐life (0.35
[0.13–1.0] minutes). EA‐230 was well tolerated and no safety concerns were
observed.
Conclusion: These dose‐escalating phase I studies with different administration
strategies reveal a pharmacokinetic profile of EA‐230 with a large volume of distribu-
tion and a short half‐life. Furthermore, EA‐230 was well tolerated and no safety
issues emerged. These results have enabled further clinical development in a phase
IIa trial assessing the pharmacodynamics of this compound during systemic inflamma-
tion described elsewhere in this issue.
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1 | INTRODUCTION
Systemic inflammation plays a detrimental role in various autoimmune
diseases, but also during critical illness, such as sepsis, trauma and
major surgery. In the latter group, an injurious systemic inflammatory
response to a variety of inflammatory stimuli may occur, often
resulting in pronounced tissue damage with associated organ failure
and mortality rates up to 30%.1-3 Despite its tremendous impact, cur-
rent intensive care consists of supportive treatment, as no pharmaceu-
tical interventions have proven effective in regulating the systemic
inflammatory response to prevent organ injury.4-6 Therefore, new
therapeutic strategies are warranted.
The adaptation of the maternal immune system during pregnancy
has provided a basis for research into new immunomodulatory strate-
gies. Pregnancy represents a unique immunologic situation in which
the maternal immune system tolerates the semi‐allogeneic fetus, while
maintaining pathogen clearing capacity.7-9 This immune‐tolerant anti‐
inflammatory phenotype is also exemplified by the fact that various
autoimmune diseases like rheumatoid arthritis (RA), multiple sclerosis
(MS) and psoriasis show attenuated disease activity during pregnancy
and often relapse following delivery.10-14
The hormonal milieu, in particular the release of human chorionic
gonadotropin (hCG), is thought to play a pivotal role.15 Produced
throughout pregnancy, hCG is already present at a very early stage
and has been shown to exert immunomodulatory effects.16-19 In addi-
tion to the integral hCG molecule, nicked fragments originating from
the β‐loop of hCG, which are abundantly present in the circulation
during pregnancy, exert immunological effects.20 Recent studies in
animal models of systemic inflammation have shown that these
oligopeptides exert immunomodulatory effects and limit organ failure
and mortality.21-29 Of particular interest is the linear tetrapeptide
alanine‐glutamine‐glycine‐valine (AQGV), which has shown the most
promising effects up till now. This peptide preserved kidney function
and substantially reduced mortality in murine models of renal ischae-
mia and reperfusion.22 Furthermore, it attenuated the release of
inflammatory mediators during haemorrhagic and endotoxemia‐
induced shock in mice and monkeys.23,24,28
AQGV is currently developed under the product name EA‐230 as a
potential novel immune modulatory compound. The present work
describes three phase I studies in which the first‐in‐human pharmaco-
kinetics, safety and tolerability of EA‐230 are investigated, using
escalating single and multiple dosages as well as escalating continuous
dosages.
2 | METHODS
2.1 | General
Double‐blind, randomized, placebo‐controlled, phase I studies in
healthy subjects were conducted to evaluate pharmacokinetics, safety
and tolerability of EA‐230 in escalating single dosages, multiple dos-
ages and single continuous dosages. Dosages were selected based
on the effective immunomodulatory dose in pre‐clinical studies, rang-
ing from 5–50 mg/kg, without exceeding the established maximum
tolerated dose of 200 mg/kg/day.22-25,28 Animal pharmacokinetic
(PK) data are summarized in the Supplemental data file. The studies
were approved by the Ethics Committee ZNA/OCMW in Antwerp
and of the Radboud University Medical Center, Nijmegen, and regis-
tered at clinicaltrial.gov (NCT02629874). All studies complied with
the Declaration of Helsinki and in compliance with the International
Conference on Harmonisation E6 Guideline for Good Clinical Practice
(CPMP/ICH/135/95). All healthy volunteers who participated in the
study provided written informed consent before the start of any
study‐related procedures. Quality assurance, data management with
full data validation, and monitoring of all source documents and study
procedures were performed by contract research organizations (SGS
Life Sciences Clinical Research Services [Antwerp, Belgium] and QPS
[Groningen, The Netherlands]).
2.2 | Study medication
EA‐230 and placebo were supplied as solution for injection in identical
sterile single‐use vials. EA‐230 vials contained 11 ml of 40 mg/ml (sin-
gle and multiple dosage studies) or 5 ml of 300 mg/ml (continuous
dosage study) active substrate, and placebo vials contained an
equivalent osmolar dose of sodium chloride solution. Vials were
manufactured by Octoplus and HAL allergy BV, and quality controlled
by PROXY Laboratories BV (both based in Leiden, The Netherlands).
Manufacturing, packaging, quality control and preparation were
described in an Investigational Medicinal Product Dossier (IMPD)
and complied with Good Manufacturing Practice (GMP) requirements.
Randomization, using a pre‐determined randomization list, and
preparation of study medication were performed by independent
What is already known about this subject
• Systemic inflammation can result in pronounced tissue
damage and is associated with organ failure and high
mortality rates.
• EA‐230 is a new, β‐hCG‐derived immunomodulatory
compound developed to modulate systemic
inflammation and to protect organs.
What this study adds
• These first phase I studies using single, multiple and
continuous dosage administration demonstrate that EA‐
230 has a non‐proportional dose‐exposure relationship,
a large volume of distribution and a very high clearance
rate.
• EA‐230 is well tolerated by healthy volunteers without
any safety concerns.
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research personnel, who were not involved in data sampling, analysis
or any other study‐related activity.
2.3 | Subjects
Following written informed consent, healthy Caucasian adult males
and females with a body mass index between 18 and 30 kg/m3 were
included. Before participation, health status was determined by medi-
cal history, physical examination, electrocardiogram (ECG) and routine
laboratory blood tests. Female subjects were also required to have a
negative pregnancy test result (urine hCG). Exclusion criteria included
atopic constitution, presence and/or history of clinically significant
allergies, use of any medication, significant blood loss and participation
in any other clinical trial within 90 days prior to the study. The use of
tobacco, recreational drugs, alcohol and/or caffeine 7 days prior to or
during the study was not allowed. All subjects were fasted from the
evening before (midnight) until 4 hours after the start of study drug
administration, to exclude any dietary effects on the PK of the
compound and for safety reasons.
2.4 | Study procedures
A schematic overview of the study procedures is presented in Figure 1.
2.4.1 | Single dosage study
Thirty‐two male subjects were assigned to one of four dosage groups:
1, 3, 10 and 30 mg/kg body weight. Each dosage group consisted of
eight subjects, randomly assigned to receive either EA‐230 or placebo
(n = 6 active study drug, n = 2 placebo).
The study drug was administered as an i.v. bolus injection in
2 minutes for dosage groups 1 and 2 (1 and 3 mg/kg), and in
15 minutes for dosage groups 3 and 4 (15 and 30 mg/kg). Frequent
blood samples for PK analyses were collected and subjects were
monitored for 24 hours.
2.4.2 | Multiple dosage study
In this subsequent 3‐day multiple dosage study, 24 healthy male vol-
unteers were assigned to three escalating dosage groups: 10, 20 and
30 mg/kg body weight. Each dosage group consisted of eight subjects
who were randomly assigned to receive either EA‐230 (n = 6) or pla-
cebo (n = 2). The study drug was administered as an i.v. bolus infusion
in 10 minutes thrice daily for three subsequent days at intervals of
8 hours (nine dosages per subject in total). Serial blood samples for
PK analyses were collected and subjects were monitored until dis-
charge 12 hours after the last dose administration. Subjects returned
at Day 14 for follow‐up.
(A)
(B)
FIGURE 1 Schematic overview of study
procedures. A, Total study period. B, Day of
study drug administration. aSafety
assessments including vital parameters, ECG,
routine haematology and biochemistry and
injection site inspection. bFor the multiple
dosage study, study drug administration and
safety assessments were performed thrice
daily for 3 days, whereas PK assessments
were performed following every first study
drug administration of the day
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2.4.3 | Continuous dosage study
Twenty‐four subjects were assigned to three dosage groups: 15, 45 or
90 mg/kg/hour EA‐230, for the duration of 2 hours. Each dosage
group consisted of eight subjects (four males and four females) and
within each dosage group subjects were randomly assigned to receive
either EA‐230 (n = 6) or placebo (n = 2), with equal numbers of males
and females within active and placebo groups. The study drug was
administered by 2‐hour continuous i.v. infusion. Serial blood samples
for PK analyses were collected and subjects were monitored until
release from the research unit 8 hours after start of study drug admin-
istration. Subjects returned at Days 1, 2, 7 and 14 after study drug
infusion for follow‐up.
2.5 | Pharmacokinetic analyses
Blood samples for measurement of EA‐230 concentrations were col-
lected from the arm opposite to the one where EA‐230 was adminis-
tered. A schematic overview of the sampling time‐points is provided in
Figure 1. For the single dosage study, samples were collected at the
following time points: prior to and at 5, 10, 15, 20, 30, 45, 60, 120
and 240 minutes after the start of study drug administration. For the
multiple dosage study, PK samples were only collected after the first
study drug administration on each day, at the same time points as in
the single dosage study. For the continuous dosage study, PK samples
were collected prior to and at 15, 30, 60, 90, 120, 180, 240, 360, 480
and 1440 minutes after start of study drug administration.
Immediately following withdrawal of 3 mL ethylenediaminetetra-
acetic acid (EDTA)‐anticoagulated blood, Protease Inhibitor Cocktail
(P8340, Sigma‐Aldrich Chemie, Zwijndrecht, The Netherlands) was
added to stabilize EA‐230 by preventing proteolysis. Blood samples
were centrifuged at 2000–2700g for 5–15 minutes at 4°C and plasma
samples were stored at −20–80°C until analysis.
EA‐230 concentrations were determined by a validated liquid
chromatography–tandem mass spectrometry (LS‐MS/MS) assay.
Briefly, a stable isotope‐labelled internal standard of EA‐230
(A*QGV; Caslo, Lyngby, Denmark) was added to 100 μL plasma
sample, followed by the addition of 300 μL of acetonitrile. Five μL
supernatant, obtained by passing the mixture through an OstroTM
96‐well plate, was injected for chromatographic separation using a
high performance liquid chromatography (HPLC) system. The reten-
tion time of EA‐230 and its stable isotope‐labelled internal standard
was 2.2 min. A tandem mass spectrometer was used for the detection
of the compounds, and quantification was based on the peak area
ratios of EA‐230 and its stable isotope labelled internal standard.
The detection range of the method was 0.5–100 ng/mL with low,
medium and high quality control (QC) concentrations of 1.5, 10 and
75 ng/mL. Concentrations below the limit of quantification were not
included in the PK analyses. Inter‐run and intra‐run precision
coefficients of variation (CV) and accuracy relative error (RE) were
determined for the low, intermediate and high concentration
standards. Inter‐run and intra‐run CV were between 4.8–8.6% and
2.1–11.4%, respectively. RE were between −2.5–8.0% and −10.6–
11.2%, respectively. EA‐230 concentrations were shown to be stable
at room temperature for 17 hours and at −80°C for up to 183 days.
The highest observed plasma concentration was defined as Cmax.
The area under the plasma concentration vs. time curve from t = 0 to
the time of the last measured concentration (AUC0‐last) was calculated
using the linear‐log trapezoidal rule, with extrapolation to infinity (using
Clast/β) to obtain the AUC from t = 0 to infinity (AUC0‐inf). The log‐linear
period (log concentration vs. time) was defined by visual inspection of
data points. The absolute value of the slope (β/2.303) was calculated
by least squares linear regression analysis, where β is the first‐order
elimination rate constant. Elimination half‐life (t1/2) was calculated
by the equation 0.693/β. Clearance (Cl) was calculated by dividing
dose by AUC0‐inf and volume of distribution (Vd) by dividing Cl by β.
2.6 | Safety and tolerability assessments
On the study drug administration days of each study, frequent safety
and tolerability assessments were performed until discharge and
rechecked during the follow‐up visits (Figure 1). Safety parameters
included vital signs (blood pressure and heart rate), 12‐lead ECG and
routine haematology and biochemistry laboratory tests. Adverse
events (AEs) were recorded throughout the study, until the final study
visit. All AEs were judged by the investigator with regard to severity
(mild, moderate or severe) according to CommonTerminology Criteria
for Adverse Events (CTCAE) guidelines 4.0,30 and their relation to the
study drug (definitely, probably, possibly or unrelated/unlikely to be
related). Serious adverse events (SAEs) included death, life‐threatening
disease, persistent and/or significant disability and/or incapacity and
hospitalization and/or prolongation of inpatient hospitalization. In
order to minimize risks in these studies, dosage groups were tested
sequentially if the previous dosage was well tolerated without relevant
adverse effects. Safety parameters were reported to an independent
Data Safety Monitoring Board (DSMB) after completion of each dos-
age group.
2.7 | Statistical analysis
Demographic data of each study are expressed as mean ± SD and
compared using one‐way analysis of variance (ANOVA). Adverse
events are summarized by treatment group, preferred term, severity
and relation to the study drug. PK parameters are presented according
to treatment group using geometric mean and 95% confidence
intervals (CI). Dose proportionality was assessed using unpaired Stu-
dent's t‐tests or one‐way ANOVA followed by a Bonferroni post‐hoc
test on dose‐normalized, log‐transformed data. Dose accumulation in
the multiple dosage study was assessed by repeated measures one‐
way ANOVA on log‐transformed data. A p‐value of <0.05 was
considered statistically significant. Statistical calculations were per-
formed using GraphPad Prism version 5.03 (GraphPad Software),
The PK analysis was performed with non‐compartmental methods
using WinNonLin/Phoenix version 6.3 (Pharsight Corporation, St.
Louis, MO, USA).
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3 | RESULTS
3.1 | Subject disposition
All subjects were Caucasian and there were no differences in baseline
characteristics between groups (Table 1). All subjects received study
medication as intended and were deemed compliant to the study pro-
tocol. In the multiple dosage study, one participant was replaced after
1 day (three dosings) for personal reasons and the replacing partici-
pant withdrew after 2 days (six dosings) for work‐related reasons.
The two subjects that did not complete the study were included in
the safety analysis as they received study medication. However,
because of incomplete PK data, these subjects could not be used for
the PK analysis.
3.2 | Single dosage study
3.2.1 | Pharmacokinetics
Plasma EA‐230 concentration–time profiles are presented in Figure 2
A and PK parameters are summarized in Table 2a. In the two lowest
dosage groups (1 and 3 mg/kg), the maximum concentration observed
was at the first time point (at t = 5 minutes, 3 minutes after
administration had stopped). In the highest dosage groups (10 and
30 mg/kg), Cmax was reached before the end of infusion (at
t = 10 minutes, 5 minutes before administration had stopped). A rapid
decline in plasma concentration was observed; concentrations
decreased below the limit of quantification for the four dosage groups
at 15, 20, 45 and 120 minutes, respectively. With regard to this rapid
decline in plasma concentrations, the elimination rate constant β and
other β‐dependent PK parameters (AUC0‐inf, t1/2, Vd, Cl) could not
be determined for the lowest dosage groups. In the two highest
dosage groups, a high volume of distribution (geometric means of 3
and 33 L/kg) and fast clearance rate (geometric means of 57 and
61 L/h/kg) were observed. Dose proportionality could not be assessed
across all dosages as the duration of administration differed between
the 1 and 3 mg/kg groups (2 minutes) and the 15 and 30 mg/kg
groups (15 minutes). Nevertheless, the dosage increase from 1 to
3 mg/kg as well as that from 10 to 30 mg/kg resulted in a proportional
increase in exposure parameters Cmax and AUC0‐last (Figure 4A).
3.2.2 | Safety and tolerability
Administration of a single dose of EA‐230 was well tolerated by all
subjects in every dosage group, and did not result in any safety
concerns. No SAEs were reported. Six subjects (25%) treated with
EA‐230 and two placebo‐treated subjects (25%) reported one or more
AEs (Table 3a). All AEs were mild and transient, and no dose‐
dependent increase in number or intensity of AEs was observed. Most
of the AEs were deemed unrelated to the study drug. Two subjects
reported AEs which were considered possibly related to the study
TABLE 1 Demographic characteristics
a. Single dosage
Placebo 1 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg
P‐valuen = 8 n = 6 n = 6 n = 6 n = 6
Gender (m), n 8 6 6 6 6
Age, years 32 ± 6 34 ± 7 40 ± 4 38 ± 9 37 ± 7 0.22
BMI, kg/m2 23.6 ± 1.7 24.5 ± 2.1 23.1 ± 2.5 22.7 ± 1.4 25.4 ± 1.3 0.11
Weight, kg 80 ± 6 79 ± 10 76 ± 10 79 ± 5 82 ± 6 0.74
Height, cm 184 ± 6 180 ± 5 181 ± 4 175 ± 6 179 ± 6 0.08
b. Multiple dosage
Placebo 10 mg/kg 20 mg/kg 30 mg/kg
P‐valuen = 6 n = 6 n = 6 n = 7
Gender (m), n 6 6 6 7 1
Age, years 29 ± 11 36 ± 11 27 ± 7 34 ± 8 0.34
BMI, kg/m2 22.3 ± 2.0 23.9 ± 3.0 23.7 ± 1.9 22.7 ± 3.7 0.70
Weight, kg 70 ± 9 79 ± 10 77 ± 10 72 ± 7 0.31
Height, cm 177 ± 8 182 ± 6 180 ± 6 179 ± 6 0.62
c. Continuous dosage
Placebo 15 mg/kg/h 45 mg/kg/h 90 mg/kg/h
P‐valuen = 6 n = 6 n = 6 n = 6
Gender (m), n 3 3 3 3 1
Age, years 22 ± 3 22 ± 2 21 ± 4 21 ± 2 0.91
BMI, kg/m2 23.1 ± 1.5 21.4 ± 1.8 21.9 ± 4.1 22.4 ± 1.4 0.67
Weight, kg 71 ± 11 66 ± 6 67 ± 16 70 ± 7 0.78
Height, cm 176 ± 8 175 ± 5 174 ± 5 178 ± 12 0.90
Parameters were determined during screening visit. BMI, body mass index. (a) Single dosage study. (b) Multiple dosage study. (c) Continuous dosage study.
Data are presented as mean ± SD.
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drug; one subject in the placebo group with mild headache and one
subject in the lowest dosage group with mild headache and dizziness
for <1 hour. Other non‐related AEs are shown in Table 4a. All
variations in laboratory parameters, vital signs and 12‐lead ECG were
considered not clinically significant.
3.3 | Multiple dosage study
3.3.1 | Pharmacokinetics
Plasma EA‐230 concentration–time profiles are presented in Figure 2
B and PK parameters are summarized in Table 2b. All subjects that
were administered EA‐230 had quantifiable values of EA‐230
5 minutes after the start of every study drug administration. Cmax
was reached both during (t = 5 min) and at the end of infusion
(t = 10 min), independent of dosage group, subject and/or day of
administration. In line with the single dosage study, a high volume
of distribution (geometric means across the three dosage groups
ranging from 4 to 21 L/kg) and high clearance rate (geometric means
across the three dosage groups ranging from 35 to 54 L/h/kg) was
observed, resulting in a rapid decline in plasma concentration with
quantifiable concentrations up to 30 minutes in the 10 mg/kg group,
up to 45 minutes in the 20 mg/kg group, and up to 1 h in the
30 mg/kg group. No accumulation in this multiple dosage study was
observed as Cmax and AUC0‐last were similar on all three days for all
three dosage groups (Figure 3). A proportional increase in exposure
parameters AUC0‐last and Cmax was observed with the dose increase
from 10 mg/kg to 20 mg/kg, whereas the dose increase to
30 mg/kg resulted in a more than proportional increase (Cmax 126%;
AUC0‐last 123%; Figure 4B).
3.3.2 | Safety and tolerability
All dosages of EA‐230, up to 90 mg/kg daily for 3 days, were well
tolerated by all subjects and did not result in any safety concerns.
No SAEs were reported, and no subjects discontinued the study for
safety reasons. Twelve subjects (61%) treated with EA‐230 and three
placebo‐treated subjects (50%) reported one or more AEs, and no
relevant dose‐dependent increase in number or intensity of AEs was
observed (Table 3b). All AEs were mild and transient (with the excep-
tion of one moderately severe AE based on a venous injection site
haemorrhage which was deemed unrelated to the study drug). Four
AEs (17%) were considered possibly related to study drug treatment;
two subjects (33%) in the lowest treatment group reported short‐
lasting postural dizziness and two subjects (33%) in the placebo group
reported headaches.
Other non‐related AEs are shown in Table 4b. All variations in
laboratory parameters, vital signs and 12‐lead ECG were considered
not clinically significant.
3.4 | Continuous dosage study
3.4.1 | Pharmacokinetics
In the lowest dosage group (15 mg/kg/h), one subject was excluded
from all PK analyses because of an abnormal pattern of plasma con-
centrations of EA‐230, with high concentrations at baseline, probably
due to an interchange of tubes.
Plasma EA‐230 concentration–time profiles are presented in
Figure 2C and PK parameters are summarized in Table 2c. In all three
dosage groups, stable plasma concentrations were attained 15 minutes
after start of EA‐230 administration. A very rapid decline in plasma
concentrations was observed after cessation of study drug administra-
tion in all groups, resulting in few measurable EA‐230 concentrations
beyond the 2‐hour time point. As a result, the elimination rate
constant β (and t1/2, Cl and Vd) could only be estimated in a limited
number of subjects, revealing a large volume of distribution (geometric
means across the three dosage groups ranging from 13 to 21 L/kg)
(A)
(B)
(C)
FIGURE 2 Plasma concentration–time profiles of EA‐230. A, Single
dosage study. B, Multiple dosage study. C, Continuous dosage study.
Data are expressed as geometric means and 95% CI. The grey areas
indicate the study drug administration periods. (For panel A: Dark grey
indicates administration period for dosage groups 1 mg/kg and
3 mg/kg, light grey for dosage groups 10 mg/kg and 30 mg/kg)
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with a rapid clearance rate (geometric means across the three dosage
groups ranging from 26 to 54 L/h/kg). The dosage increase from
15 mg/kg/h to 45 mg/kg/h resulted in proportional increase in Cmax
and AUC0‐last, but a more than proportional increase in these exposure
parameters occurred upon a dosage increase to 90 mg/kg/h (Cmax
136%; AUC0‐last 137%; Figure 4C).
TABLE 2 Pharmacokinetic parameters of EA‐230
a. Single dosage n 1 mg/kg n 3 mg/kg n 10 mg/kg n 30 mg/kg
AUC‐0‐last (h*μg/L) 6 2 (1–4) 6 8 (5–13) 6 175 (98–312) 6 490 (363–660)
AUC0‐inf (h*μg/L) – – 6 175 (98–312) 6 490 (364–660)
Cmax (μg/L) 6 27 (14–55) 6 115 (64–208) 6 1336 (672–2656) 6 3071 (2133–4421)
t1/2 (h) – – 6 0.04 (0.02–0.07) 6 0.37 (0.16–0.85)
CL (L/h/kg) – – 6 57 (32–102) 6 61 (45–82)
Vd (L/kg) – – 6 3 (2–5) 6 33 (12–87)
b. Multiple dosage n 10 mg/kg n 20 mg/kg n 30 mg/kg
AUC0‐last (h*μg/L) 6 6 5
Day 1 270 (161–454) 506 (387–662) 645 (357–1167)
Day 2 241 (98–592) 393 (227–682) 560 (364–861)
Day 3 273 (100–752) 565 (421–760) 572 (436–751)
AUC0‐inf (h*μg/L) 6 6 5
Day 1 271 (162–453) 506 (387–662) 646 (357–1167)
Day 2 242 (98–592) 393 (227–682) 560 (365–862)
Day 3 273 (100–752) 566 (421–760) 572 (437–751)
Cmax (μg/L) 6 6 5
Day 1 2295 (1279–4118) 4390 (3207–6008) 5816 (3618–9349)
Day 2 2242 (945–5323) 3504 (2243–5474) 4807 (3080–7501)
Day 3 2416 (855–6826) 4540 (3382–6093) 5096 (4050–6412)
t1/2 (h) 6 6 5
Day 1 0.09 (0.04–0.20) 0.14 (0.11–0.17) 0.24 (0.22–0.26)
Day 2 0.06 (0.04–0.11) 0.14 (0.08–0.25) 0.25 (0.21–0.31)
Day3 0.07 (0.05–0.11) 0.13(0.11–0.16) 0.27 (0.22–0.36)
CL (L/h/kg) 6 6 5
Day 1 36 (22–62) 40 (30–52) 46 (26–84)
Day 2 41 (17–102) 51 (29–88) 54 (35–82)
Day3 37 (13–100) 35 (26–48) 52 (40–69)
Vd (L/kg) 6 6 5
Day 1 5 (2–14) 8 (5–12) 16 (9–28)
Day 2 4 (1–11) 10 (6–18) 19 (12–30)
Day3 4 (1–11) 7 (5–10) 21 (13–35)
c. Continuous dosage n 15 mg/kg/h n 45 mg/kg/h n 90 mg/kg/h
AUC0‐last (h*μg/L) 5 502 (207–1217) 6 1511 (1094–2088) 6 7344 (4458–12098)
AUC0‐inf (h*μg/L) 2 553 (–) 2 1534 (–) 2 7050 (–)
Cmax (μg/L) 5 441 (193–1011) 6 1385 (849–2261) 6 6785 (4409–10441)
t1/2 (h) 2 0.24 (–) 5 0.25 (0.14–0.45) 4 0.35 (0.13–1.0)
CL (L/h/kg) 2 54 (–) 5 59 (38–90) 4 26 (15–43)
Vd (L/kg) 2 19 (–) 5 21 (12–37) 4 13 (3–58)
Data expressed as geometric means and 95% CI (No 95% CI for data with n = 2). t1/2, elimination half‐life; Cmax, highest observed plasma concentration;
AUC0‐last, the area under the plasma versus concentration time curve from t = 0 to the time of the last measured concentration; AUC0‐inf, the area under
the plasma versus concentration time curve from t = 0 to infinity extrapolated; Cl, plasma clearance; Vd, volume of distribution.
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3.4.2 | Safety and tolerability
Continuous infusion of EA‐230 was well tolerated by all subjects in
every dosage group, and did not result in any safety concerns and/or
discontinuation of study drug administration. No SAEs were reported.
Eight subjects (44%) treated with EA‐230 and one placebo‐treated
subject (17%) reported one or more AEs (Table 3c). All AEs were mild
and transient, and considered unlikely to be or not related to the study
drug. Short‐lasting dizziness was observed in two subjects in the
highest dosage group (33%), and ceased after eating in one subject.
Flu‐like symptoms were reported by two subjects in the intermediate
(17%) and highest dosage group (17%), both starting at least 24 hours
TABLE 3 Summary of adverse events
a. Single dosage
Placebo (n = 8) 1 mg/kg (n = 6) 3 mg/kg (n = 6) 10 mg/kg (n = 6) 30 mg/kg (n = 6) Overall (n = 32)
n (%) n (%) n (%) n (%) n (%) n (%)
Any AE 2 (25) 1 (16.7) 2 (33.3) 2 (33.3) 1 (16.7) 8 (25)
Any SAE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued due to (S)AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Concomitant medication given 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE of mild intensity 2 (25) 1 (16.7) 2 (33.3) 2 (33.3) 1 (16.7) 8 (25)
AE of moderate intensity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE of severe intensity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Definitely related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Probably related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Possibly related AE 1 (12.5) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.3)
Unlikely related/unrelated AE 1 (12.5) 0 (0.0) 2 (33.3) 2 (33.3) 1 (16.7) 6 (18.7)
b. Multiple dosage
Placebo (n = 6) 10 mg/kg (n = 6) 20 mg/kg (n = 6) 30 mg/kg (n = 7) Overall (n = 25)
n (%) n (%) n (%) n (%) n (%)
Any AE 3 (50.0) 3 (50.0) 4 (76.7) 5 (71.4) 15 (60.0)
Any SAE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued due to AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Concomitant medication given 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE of mild intensity 3 (50.0) 3 (50.0) 3 (50.0) 5 (71.4) 15 (60.0)
AE of moderate intensity 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0)
AE of severe intensity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Definitely related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Probably related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Possibly related AE 2 (33.3) 2 (33.3) 0 (0.0) 0 (0.0) 4 (16.0)
Unlikely related/unrelated AE 1 (16.7) 1 (16.7) 4 (76.7) 5 (71.4) 11 (44.0)
c. Continuous dosage
Placebo (n = 6) 15 mg/kg/h (n = 6) 45 mg/kg/h (n = 6) 90 mg/kg/h (n = 6) Overall (n = 24)
n (%) n (%) n (%) n (%) n (%)
Any AE 1 (16.7) 1 (16.7) 3 (50.0) 4 (66.7) 9 (37.5)
Any SAE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued due to AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Concomitant medication given 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE of mild intensity 1 (16.7) 1 (16.7) 3 (50.0) 4 (66.7) 9 (37.5)
AE of moderate intensity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE of severe intensity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Definitely related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Probably related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Possibly related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unlikely related/unrelated AE 1 (16.7) 1 (16.7) 3 (50.0) 5 (83.3) 10 (41.7)
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TABLE 4 Summary of adverse events by system organ class and preferred term
a. Single dosage
Placebo (n = 8) 1 mg/kg (n = 6) 3 mg/kg (n = 6) 10 mg/kg (n = 6) 30 mg/kg (n = 6) Overall (n = 32)
System organ class and preferred term n (%) e n (%) e n (%) e n (%) e n (%) e n (%) e
Number of subjects with at least one AE 2 (25.0) 4 1 (16.7) 2 2 (33.3) 4 2 (33.3) 2 1 (16.7) 1 8 (25.0) 13
General disorders 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 1 (16.7) 1 1 (16.7) 1 3 (9.4) 3
Catheter site related reaction 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 1 (16.7) 1 2 (6.3) 2
Nasopharingitis 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 1 (3.1) 1
Nervous system disorders 1 (12.5) 1 1 (16.7) 2 2 (33.3) 3 0 (0.0) 0 0 (0.0) 0 4 (12.5) 6
Dizziness postural 0 (0.0) 0 1 (16.7) 1 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 2 (6.3) 2
Headache 1 (12.5) 1 1 (16.7) 1 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 3 (9.4) 3
Paresthesia 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 1 (3.1) 1
Gastrointestinal disorders 1 (12.5) 2 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (3.1) 2
Abdominal pain 1 (12.5) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (3.1) 1
Flatulence 1 (12.5) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (3.1) 1
Musculoskeletal disorders 1 (12.5) 1 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 2 (6.3) 2
Back pain 1 (33.3) 1 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 1 (3.1) 1
Chest pain 1 (12.5) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (3.1) 1
b. Multiple dosage
Placebo (n = 6) 10 mg/kg (n = 6) 20 mg/kg (n = 6) 30 mg/kg (n = 7) Overall (n = 25)
System organ class and preferred term n (%) e n (%) e n (%) e n (%) e n (%) e
Number of subjects with at least one AE 3 (50.0) 5 3 (50.0) 6 4 (76.7) 6 5 (71.4) 6 15 (60.0) 23
General disorders 1 (16.7) 1 1 (16.7) 1 4 (76.7) 4 3 (42.9) 3 8 (32.0) 8
Catheter site related reaction 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 1 (14.3) 1 2 (8.0) 2
Injection site haemorrhage 1 (16.7) 1 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 2 (8.0) 2
Fatigue 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 1 (14.3) 1 2 (8.0) 2
Nasopharingitis 0 (0.0) 0 0 (0.0) 0 2 (33.3) 2 1 (14.3) 1 3 (12.0) 3
Nervous system disorders 2 (33.3) 2 2 (33.3) 2 1 (16.7) 1 0 (0.0) 0 5 (20.0) 5
Dizziness postural 0 (0.0) 0 2 (33.3) 2 0 (0.0) 0 0 (0.0) 0 2 (8.0) 2
Headache 2 (33.3) 2 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 3 (12.0) 3
Musculoskeletal disorders 2 (33.3) 2 0 (0.0) 0 0 (0.0) 0 2 (28.6) 2 4 (16.0) 4
Back pain 2 (33.3) 2 0 (0.0) 0 0 (0.0) 0 2 (28.6) 2 4 (16.0) 4
Gastrointestinal disorders 0 (0.0) 0 1 (16.7) 1 1 (16.7) 1 1 (14.3) 1 3 (12) 3
Abdominal pain 0 (0.0) 0 1 (16.7) 1 1 (16.7) 1 0 (0.0) 0 2 (8.0) 2
Constipation 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (14.3) 1 1 (4.0) 1
(Sub)cutaneous disorders 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 1 (4.0) 1
Eczema 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 1 (4.0) 1
Vascular disorders 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 1 (4.0) 1
Peripheral coldness 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 1 (4.0) 1
c. Continuous dosage
Placebo (n = 6) 15 mg/kg/h (n = 6) 45 mg/kg/h (n = 6) 90 mg/kg/h (n = 6) Overall (n = 24)
System organ class and preferred term n (%) e n (%) e n (%) e n (%) e n (%) e
Number of subjects with at least one AE 1 (16.7) 1 1 (16.7) 1 3 (33.3) 4 4 (66.7) 8 8 (33.3) 14
General disorders 0 (0.0) 0 0 (0.0) 0 1 (16.7) 2 3 (50.0) 3 4 (16.7) 5
Catheter site related reaction 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 2 (33.3) 2 2 (8.3) 2
Influenza like illness 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 1 (16.7) 1 2 (8.3) 2
Infusion site reaction 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 1 (4.2) 1
(Continues)
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after cessation of study drug administration and lasting for a maximum
of 1 day. Gastrointestinal complaints (nausea and soft stool) were
reported by two subjects in the intermediate (17%) and highest dos-
age group (17%), starting shortly after dinner >8 hours after cessation
of study drug administration and disappeared the same evening. Other
non‐related AEs are summarized in Table 4c. All variations in labora-
tory parameters, vital signs and 12‐lead ECG were considered not
clinically significant.
4 | DISCUSSION
In this study, we describe the pharmacokinetics, safety and tolerability
of EA‐230 in healthy volunteers using different administration strate-
gies and increasing dosages in three double‐blind, randomized,
placebo‐controlled, phase I studies. Our data reveal that EA‐230 has
a large volume of distribution and a very rapid plasma clearance. A
more than proportional increase in exposure with the highest dosages
was observed and no accumulation occurred during the multiple
dosage study. The drug was well tolerated and showed an excellent
safety profile throughout the investigated dose range.
For the majority of subjects receiving dosages of 10 mg/kg or
more in both the first and the second study, Cmax was reached before
the end of infusion, while in theory Cmax is expected to be reached at
the end of infusion. This observation implies a very rapid distribution
of EA‐230 and/or clearance rates that may have exceeded the rate
of infusion. This assumption is further supported by the PK profile
observed during continuous infusion, where EA‐230 reached steady
state concentrations already at the first sampling point 15 minutes
after the start of administration, indicating rapid distribution and a
rapid systemic clearance rate.
All three studies showed a large volume of distribution and a very
rapid clearance, resulting in a short half‐life, confirming previous
animal data (see Supplemental data file) . However, with regard to
the short half‐life, we were only able to provide an estimate of these
variables, representing a limitation of this study. In the bolus infusion
studies, low concentrations approaching the limit of detection were
observed already early after administration, therefore only limited
time points were available and concentrations close to the limit of
TABLE 4 (Continued)
c. Continuous dosage
Placebo (n = 6) 15 mg/kg/h (n = 6) 45 mg/kg/h (n = 6) 90 mg/kg/h (n = 6) Overall (n = 24)
System organ class and preferred term n (%) e n (%) e n (%) e n (%) e n (%) e
Nervous system disorders 1 (16.7) 1 1 (16.7) 1 0 (0.0) 0 2 (33.3) 2 4 (16.7) 4
Dizziness 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 2 (33.3) 2 2 (8.3) 2
Head discomfort 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (4.2) 1
Somnolence 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 0 (0.0) 0 1 (4.2) 1
Gastrointestinal disorders 0 (0.0) 0 0 (0.0) 0 1 (16.7) 2 1 (16.7) 2 2 (8.3) 4
Nausea 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 1 (16.7) 1 2 (8.3) 2
Upper abdominal pain 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 1 (4.2) 1
Soft faeces 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 0 (0.0) 0 1 (4.2) 1
Eye disorders 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 1 (4.2) 1
Ocular discomfort 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (16.7) 1 1 (4.2) 1
AE, adverse events; e, number of events; n, number of subjects.
(A) (B) (C)
FIGURE 3 Dose accumulation of Cmax and AUC0‐last during the 3‐day multiple dosage study. A, Dosage group 10 mg/kg (n = 6). B, Dosage group
20 mg/kg (n = 6). C, Dosage group 30 mg/kg (n = 5). Linear regression lines are shown, dotted lines indicate the 95% confidence interval. No
accumulation was observed
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detection may have been inaccurate. In the continuous infusion study,
EA‐230 concentrations were only measurable in a limited number of
subjects and samples, also illustrative of the short half‐life of the com-
pound. As a result, we report the range related to the determinations
of the elimination constant dependent PK parameters (AUC0‐inf, t1/2,
Vd, Cl). Nevertheless, consistent findings on t1/2, Cl and Vd among
all conducted studies with different administration strategies demon-
strate a similar PK profile of EA‐230 with a large distribution volume
of at least 1 L/kg, a high clearance rate of at least 13 L/kg/h and a
short half‐life of less than 60 minutes. This PK profile indicates EA‐
230 to be very rapidly metabolized with plasma clearance exceeding
both renal and portal flow, suggesting clearance of EA‐230 through
hydrolysis, proteolysis by systemic proteases and/or cellular uptake
or tissue/protein binding. Of interest, Teftsin, a similar linear
tetrapeptide with immunomodulatory properties that has been exten-
sively investigated, is also characterized by fast degradation due to
proteolysis in vivo with a half‐life of 16 minutes.31,32 Similar mecha-
nisms of degradation might play a role in the fast elimination of EA‐
230; however, exact mechanisms of metabolism and drug clearance
need to be further elucidated.
In the multiple and continuous dosage studies, a nonlinear dose–
exposure relationship was observed with the highest dosage only,
both for total exposure (AUC0‐last) and maximal exposure (Cmax). This
non‐linear PK behaviour of EA‐230 implies a saturation effect at a
certain dosage. This could be caused by a dose‐dependent shift in
distribution, metabolism and/or elimination.
An excellent safety and tolerability profile were observed for
EA‐230 as no SAEs were reported, AEs were mild and transient, did
not result in discontinuation of study drug administration and the vast
majority of the AEs observed were deemed unlikely to be or not
related to the study drug. Six AEs were considered possibly related
to the study drug, but the evidence for the relationship between these
AEs and study drug administration is unconvincing for several reasons.
First, 50% of these AEs were observed in subjects treated with
placebo. Second, the other AEs were all observed in the lowest dosage
groups of each particular study. Noteworthy, there were no possible
related AEs reported in the study where continuous infusion of
EA‐230 was employed, which resulted in the highest plasma concen-
trations and the longest exposure to the drug. Nevertheless, in this
continuous infusion study, only one AE occurred in the placebo group
compared with eight AEs in the treatment groups, with more AEs
occurring in the higher dosage groups, indicating that a possible rela-
tion to the study drug cannot be entirely excluded. Upon review of
the specific AEs, complaints of dizziness were reported in all studies.
In the bolus studies, all possible related AEs in subjects with active
treatment were complaints of (postural) dizziness. Also, in the contin-
uous infusion study, although considered unlikely or not related, dizzi-
ness was observed in two subjects in the highest dosage groups.
Although this pattern of complaints of dizziness might indicate a rela-
tion with administration of EA‐230, similar complaints could well be
explained by the long period of fasting by these subjects in all three
studies. Furthermore, no changes in vital parameters between groups
(A) (B) (C)
FIGURE 4 Dose proportionality of dose‐normalized, log‐transformed exposure parameters Cmax and AUC0‐last. A, Single dosage study, dose
proportionality could not be assessed across all dosages as the administration duration differed between the 1 and 3 mg/kg groups (2 minutes)
and the 15 and 30 mg/kg groups (15 minutes). B, Multiple dosage study, as no dose accumulation was observed in this study (see Figure 3), the
average values over the 3 days for each subject were used. C, Continuous dosage study. A p‐value of <0.05 indicates non‐proportionality. Linear
regression lines are shown, dotted lines indicate the 95% confidence interval
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were present in all studies (data not shown), nor did preclinical data
indicate any effect of EA‐230 on blood pressure or heart rate (unpub-
lished data). Therefore, it appears unlikely that the reported dizziness
would be related to haemodynamic effects. Taking into account all
available data on safety and tolerability, no relevant safety issues for
the i.v. administration of EA‐230 to humans within the dosage range
tested were observed. Although sample sizes were relatively small,
and therefore side‐effects that are rare might still go unnoticed, the
proposed sample sizes were selected in line with generally used sam-
ple sizes for first‐in‐human phase I studies. The total of 80 volunteers
in the three phase I studies with EA‐230 would generally be regarded
as sufficient. Based on these results, a phase IIa study in volunteers
exposed to endotoxin has been conducted to investigate the
immunomodulating properties of EA‐230 (described elsewhere in this
issue33) and a clinical trial in cardiac surgery patients has been
initiated.34
In conclusion, these dose‐escalating phase I studies with different
administration strategies, describe a PK profile of EA‐230 with a large
volume of distribution and a short half‐life, and demonstrate that i.v.
administration is well tolerated without any safety issues emerging.
These results enable further clinical development to assess safety, tol-
erability and immune modulating efficacy in humans during systemic
inflammation.
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